Affordable Access

Publisher Website

Serological tests for COVID-19: Potential opportunities.

Authors
  • Tantuoyir, Marcarious M1, 2, 3
  • Rezaei, Nima1, 4, 5
  • 1 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 2 Biomedical Engineering Unit, University of Ghana Medical Center (UGMC), Accra, Ghana. , (Ghana)
  • 3 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Accra, Ghana. , (Ghana)
  • 4 Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. , (Iran)
  • 5 Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. , (Iran)
Type
Published Article
Journal
Cell Biology International
Publisher
Wiley (John Wiley & Sons)
Publication Date
Apr 01, 2021
Volume
45
Issue
4
Pages
740–748
Identifiers
DOI: 10.1002/cbin.11516
PMID: 33289157
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus, caused a pandemic leading to a standstill of nearly all global activities. There are some controversies on the production of specific immunoglobulin M (IgM) and IgG antibodies after the infection with SARS-CoV-2. This paper seeks to elaborate on the potential application of IgM and IgG antibodies and the viral antigens for the diagnosis and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. © 2020 International Federation for Cell Biology.

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. This record was last updated on 07/26/2022 and may not reflect the most current and accurate biomedical/scientific data available from NLM. The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/33289157
Report this publication

Statistics

Seen <100 times